Quantcast

Jubilant and AstraZeneca Announce Successful Delivery of Early Milestones in Drug Discovery

June 23, 2011

BANGALORE, India, June 23, 2011 /PRNewswire/ –

Jubilant Biosys Ltd., Bengaluru, based subsidiary of Jubilant Life
Sciences Ltd., and AstraZeneca, today announced another successful delivery
of an early stage milestone in the Pain therapeutic area.

The collaboration, initiated two years ago in the Neuroscience
therapeutic area, has now expanded to Cardiovascular and Metabolic diseases
and focuses on the delivery of a steady stream of preclinical outcomes to
AstraZeneca, by Jubilant. AstraZeneca owns the compounds developed under the
collaboration with worldwide development and commercialization rights.
Jubilant derives research funding and success-based development and
commercialization milestones.

Commenting on this development,Sri Mosur, CEO & President, Global Drug
Discovery & Development, Jubilant said: “We are pleased that we have
delivered outcomes and early success to the portfolio efforts at
AstraZeneca. This is the result of excellent collaboration between
scientists at Jubilant and AstraZeneca.

“Partnering is a strategic priority for AstraZeneca at all stages of
drug discovery and development,” says Christof Angst, CNS & Pain Innovative
Medicines, Vice-President, Strategy and Externalisation. “By combining our
strengths with those of our partners, we are in a better position to deliver
new medicines that can make a meaningful difference to patients’ lives.”

About Us

Jubilant Biosys Ltd. is a Bengaluru based subsidiary of Jubilant Life
Sciences Ltd, headquartered in Noida, India. Jubilant Biosys, provides
integrated drug discovery and development solutions to the global
pharmaceutical industry. It is a pioneer in collaborative discovery research
and development and is engaged in multiple partnerships with global
pharmaceutical industry in therapeutic areas of Oncology, CNS and CVMED.

http://www.jubilantbiosys.com

AstraZeneca is a global, innovation-driven biopharmaceutical business
with a primary focus on the discovery, development and commercialization of
prescription medicines for gastrointestinal, cardiovascular, neuroscience,
respiratory and inflammation, oncology and infectious disease. AstraZeneca
operates in over 100 countries and its innovative medicines are used by
millions of patients worldwide.

http://www.astrazeneca.com

Contact For Business Queries

narendra_kumar@jubilantbiosys.com , +91-9611104886

SOURCE Jubilant Biosys Ltd.


Source: newswire



comments powered by Disqus